GO:0035562 negative regulation of chromatin binding: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035562 (negative regulation of chromatin binding) is a biological process that stops or reduces the selective interaction of proteins with chromatin, the DNA-protein-RNA fiber network of the eukaryotic nucleus.
• It is mechanistically distinct from chromatin remodeling or histone modification; it acts on the binding step itself, often by post-translational modification, competitive displacement, or degradation of chromatin-bound factors.
• Key regulators include CTCF, UBR5, SUMOylation machinery, PBAF/cBAF subunits, and lamina-associated domain proteins that control access to chromatin.
• Dysregulation of this process contributes to senescence-associated inflammation, prostate cancer hormone resistance, and altered 3D genome organization.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test causality of candidate negative regulators of chromatin binding.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to dissect GO:0035562 in disease-relevant contexts.
Description
GO:0035562, negative regulation of chromatin binding, is a Gene Ontology biological process that describes any mechanism which stops or reduces the frequency, rate, or extent of chromatin binding. Chromatin binding itself is the selective interaction with chromatin, the dynamic network of DNA, histone and non-histone proteins, and RNA that packages the eukaryotic genome during interphase. Because chromatin binding underlies transcription, replication, DNA repair, and genome architecture, its negative regulation is a central control point for cell fate and disease. Researchers study GO:0035562 to understand how cells evict or exclude proteins from chromatin, how this shapes transcriptional programs, and how its failure drives pathologies such as cancer and senescence. The process is not a single molecular event but a convergence of post-translational modifications, competitive binding, targeted degradation, and nuclear architecture changes that together tune chromatin occupancy. This article integrates the QuickGO definition with verified PubMed literature to provide a publication-ready overview of the mechanisms, genes, disease links, and experimental methods relevant to GO:0035562.
negative regulation of chromatin binding At A Glance
| GO ID | GO:0035562 |
|---|---|
| GO term | negative regulation of chromatin binding |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops or reduces the frequency, rate or extent of selective interaction with chromatin |
| Parent process | Regulation of chromatin binding |
| Related process | Chromatin organization, gene repression, nuclear architecture |
| Cellular context | Eukaryotic nucleus during interphase |
| Example regulators | CTCF, UBR5, SUMOylation enzymes, PBAF/cBAF, lamina-associated proteins |
What Is GO:0035562?
In our own words, GO:0035562 refers to any cellular process that decreases the selective association of a molecule, usually a protein, with chromatin. Chromatin is the fibrous complex of DNA, protein, and sometimes RNA that forms chromosomes in the interphase nucleus. Negative regulation of chromatin binding therefore includes mechanisms that reduce the on-rate, increase the off-rate, or prevent the stable occupancy of chromatin by binding factors. It is a regulatory process that acts on the binding interaction itself, rather than on downstream chromatin-templated events.
Why Is negative regulation of chromatin binding Important in Cell Biology?
Negative regulation of chromatin binding is important because it determines which proteins are allowed to occupy the genome and for how long. By controlling chromatin occupancy, cells can rapidly reprogram transcription, silence repetitive elements, and maintain genome stability. Defects in this process are linked to senescence-associated inflammation, hormone-dependent cancers, and altered 3D chromatin structure. Understanding GO:0035562 therefore provides mechanistic insight into gene regulation and identifies candidate targets for therapeutic intervention.
• Controls transcriptional output by limiting access of transcription factors and cofactors to chromatin.
• Prevents inappropriate loading of recombination and repair factors, as shown for FIGNL1-FIRRM in meiosis.
• Regulates nuclear hormone receptor stability and signaling through chromatin-associated complexes such as UBR5.
• Shapes 3D chromatin architecture via CTCF O-GlcNAcylation and SUMOylation-dependent interactions.
• Contributes to senescence-associated inflammation by modulating cytoplasmic chromatin formation.
• Maintains lamina-associated domain repression and heterochromatin organization.
• Influences circadian gene regulation through PBAF/cBAF reorganization on H3.3 chromatin.
• Provides a mechanistic basis for understanding prostate cancer androgen receptor resistance.
• Offers targets for CRISPR-based functional screens in cancer and aging research.
• Helps explain how yeast GAL gene expression is controlled by chromatin structure.
What Happens During negative regulation of chromatin binding?
Initiation: sensing chromatin-bound factors
In simple terms: The cell first detects that a protein is bound to chromatin and decides to remove or reduce that binding.
Negative regulation of chromatin binding begins with recognition of a chromatin-bound factor that must be displaced or prevented from rebinding. This can occur through post-translational modification of the chromatin-bound protein, such as O-GlcNAcylation of CTCF, which alters its chromatin interactions. In senescence, mitochondria-to-nucleus retrograde signaling triggers formation of cytoplasmic chromatin and inflammatory responses, reflecting a shift in chromatin binding regulation. The initiation step is therefore context-dependent and often linked to cellular stress or signaling cues.
Execution: modification, competition, or degradation
In simple terms: The cell uses chemical tags, competing molecules, or degradation to push the protein off chromatin.
Execution of negative regulation can involve SUMOylation, which regulates chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells. UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability, effectively reducing sustained chromatin binding. Competitive displacement by other factors, as seen in PBAF/cBAF reorganization on H3.3 chromatin, can also reduce binding of BMAL1 in the absence of circadian negative feedback. These mechanisms converge on lowering the occupancy of specific proteins on chromatin.
Chromatin context and 3D architecture
In simple terms: The shape and compartmentalization of chromatin influence whether a protein can bind or must be removed.
Chromatin context is critical: lamina-associated domains involve chromatin protein complexes that mediate gene repression, and disruption of these complexes alters binding regulation. CTCF O-GlcNAcylation regulates 3D chromatin structure, showing that negative regulation of chromatin binding is intertwined with higher-order genome organization. Yeast chromatin structure and GAL gene regulation illustrate how chromatin state controls factor binding in a model organism. Thus, the process operates within a dynamic architectural framework.
Outcomes: transcriptional and cellular consequences
In simple terms: Once binding is reduced, gene expression and cell behavior change.
The outcome of negative regulation of chromatin binding is altered transcriptional programs. In prostate cancer, SUMOylation-dependent regulation of androgen receptor chromatin interactions changes transcriptional outputs. In senescence, retrograde signaling and cytoplasmic chromatin formation drive inflammation. In meiosis, FIGNL1-FIRRM prevents DNA damage-independent RAD51 and DMC1 loading, highlighting a role in recombination control. These outcomes link GO:0035562 to cell fate, inflammation, and genome stability.
Key Genes Involved in GO:0035562 negative regulation of chromatin binding
The following genes and proteins are experimentally implicated in negative regulation of chromatin binding or in chromatin binding regulation more broadly, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTCF | Chromatin architectural protein; O-GlcNAcylation regulates its chromatin interactions | 3D chromatin structure regulation |
| UBR5 | E3 ubiquitin ligase forming ligand-dependent chromatin complexes | Nuclear hormone receptor stability |
| AR | Androgen receptor; SUMOylation regulates its chromatin interactions | Prostate cancer transcriptional output |
| FIGNL1 | Meiotic recombination regulator; prevents RAD51/DMC1 loading | DNA damage-independent recombination control |
| FIRRM | Partner of FIGNL1 in meiotic recombination | Prevents inappropriate RAD51/DMC1 chromatin loading |
| BMAL1 | Circadian transcription factor; activity regulated by PBAF/cBAF on H3.3 chromatin | Circadian negative feedback |
| PBAF/cBAF subunits | Chromatin remodeling complexes reorganizing on H3.3 | BMAL1 activity regulation |
| SUMOylation enzymes | Post-translational modifiers of chromatin-binding proteins | AR chromatin interactions in prostate cancer |
| Lamina-associated domain proteins | Chromatin protein complexes mediating gene repression | Heterochromatin organization |
| GAL genes (yeast) | Model for chromatin structure and gene expression | Yeast GAL regulation |
| RAD51 | Recombinase loaded onto chromatin during meiosis | Prevented from loading by FIGNL1-FIRRM |
| DMC1 | Meiotic recombinase | Prevented from loading by FIGNL1-FIRRM |
| H3.3 | Histone variant enriched at active chromatin | PBAF/cBAF reorganization |
| Nuclear hormone receptors | Ligand-dependent transcription factors | UBR5-mediated stability regulation |
| Senescence-associated chromatin factors | Mediate cytoplasmic chromatin formation | Inflammation in senescence |
How Is negative regulation of chromatin binding Regulated?
Negative regulation of chromatin binding is itself regulated by post-translational modifications, signaling pathways, and nuclear architecture. SUMOylation directly modulates chromatin interactions of the androgen receptor in prostate cancer cells. O-GlcNAcylation of CTCF regulates 3D chromatin structure, providing a glycosylation-dependent layer of control. UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability, linking ubiquitin signaling to chromatin binding. Mitochondria-to-nucleus retrograde signaling drives cytoplasmic chromatin formation in senescence, indicating that metabolic and stress signals feed into this process. PBAF/cBAF reorganization on H3.3 chromatin regulates BMAL1 activity, connecting circadian feedback to chromatin binding control. Lamina-associated domain protein complexes mediate gene repression, showing that nuclear envelope tethering also regulates chromatin binding.
negative regulation of chromatin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AR | Prostate cancer hormone resistance | Knockout or point-mutation of SUMOylation sites in AR |
| UBR5 | Nuclear hormone receptor stability in cancer | Knockout and tagged knock-in of UBR5 |
| CTCF | 3D chromatin structure and cancer | Point mutation of O-GlcNAcylation sites |
| FIGNL1 | Meiotic recombination defects | Knockout in germ cells |
| BMAL1 | Circadian rhythm disorders | Knock-in of H3.3 chromatin binding mutants |
Cancer and hormone resistance
In prostate cancer, SUMOylation regulates chromatin interactions and transcriptional outputs of the androgen receptor, directly impacting hormone-dependent gene expression. UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability, suggesting that dysregulated negative regulation of chromatin binding can sustain oncogenic transcription. These findings position GO:0035562 as a potential therapeutic axis in hormone-driven cancers.
Senescence and inflammation
Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence, a process that involves altered chromatin binding regulation. This links negative regulation of chromatin binding to aging-related inflammation and suggests that modulating this process could influence senescence-associated pathologies.
Genome instability and meiotic defects
FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading, highlighting how failure to negatively regulate chromatin binding can cause inappropriate recombinase loading. Such defects can lead to genome instability and meiotic failure.
Circadian and metabolic disorders
PBAF/cBAF reorganization on H3.3 chromatin regulates BMAL1 activity in the absence of circadian negative feedback, connecting negative regulation of chromatin binding to circadian rhythm control. Disruption of this process may contribute to circadian and metabolic disorders.
From negative regulation of chromatin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase chromatin binding? | CRISPR knockout cell line |
| Does a specific post-translational modification site regulate chromatin binding? | Point-mutation knock-in |
| Does a disease-associated variant alter chromatin occupancy? | Knock-in of patient variant |
| Where and when does a protein bind chromatin? | Tagged knock-in for imaging or ChIP |
| Does overexpression of a regulator reduce chromatin binding? | Overexpression cell model |
| Which genes regulate chromatin binding genome-wide? | CRISPR library screening |
How to Study the negative regulation of chromatin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide chromatin occupancy | Assess binding changes after knockout |
| Proteomics | Protein complexes and modifications | Identify chromatin-associated factors |
| Hi-C | 3D chromatin interactions | Evaluate architectural changes |
| CRISPR screen | Gene function at scale | Discover negative regulators |
| Live-cell imaging | Dynamic chromatin binding | Track factor loading in real time |
| ATAC-seq | Chromatin accessibility | Measure open chromatin changes |
| Co-IP | Protein-protein interactions | Validate chromatin complex formation |
Chromatin immunoprecipitation and sequencing
ChIP-seq measures the genome-wide occupancy of chromatin-binding proteins. It is used to assess changes in binding upon knockout or point mutation of candidate negative regulators.
Proteomics and interactomics
Mass spectrometry-based proteomics identifies chromatin-associated complexes and post-translational modifications. UBR5 chromatin complexes and SUMOylation targets have been characterized using such approaches.
Imaging and nuclear architecture
Advanced imaging and chromosome conformation capture techniques reveal 3D chromatin structure changes. CTCF O-GlcNAcylation effects on 3D chromatin structure were studied using such methods.
Functional genomics screens
CRISPR knockout and activation screens identify genes that regulate chromatin binding. These screens are powerful for discovering novel negative regulators in disease models.
How CRISPR Can Be Used to Study GO:0035562 negative regulation of chromatin binding
Knockout
CRISPR knockout of candidate genes such as UBR5 or lamina-associated domain proteins can test whether loss of function increases chromatin binding and alters transcriptional outputs.
Point Mutation
Point mutation of specific post-translational modification sites, such as CTCF O-GlcNAcylation sites or AR SUMOylation sites, allows precise testing of their role in negative regulation of chromatin binding.
Knock-in
Knock-in of tagged alleles or disease-associated variants enables tracking of chromatin binding dynamics and assessment of variant effects on occupancy.
Overexpression
Overexpression of negative regulators can reduce chromatin binding of target proteins and suppress downstream transcription, providing gain-of-function evidence.
How EDITGENE Supports negative regulation of chromatin binding Research
Researchers studying negative regulation of chromatin binding-related genes often need to determine whether a candidate gene is causally involved in controlling chromatin occupancy. EDITGENE provides the CRISPR cell models and screening services required to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of chromatin binding research.
Frequently Asked Questions About negative regulation of chromatin binding
What is negative regulation of chromatin binding?
It is a biological process (GO:0035562) that stops or reduces the selective interaction of proteins with chromatin, the DNA-protein-RNA network of the nucleus.
What genes are involved in negative regulation of chromatin binding?
Genes include CTCF, UBR5, AR, FIGNL1, FIRRM, BMAL1, and PBAF/cBAF subunits, as shown in chromatin and hormone signaling studies.
How is chromatin binding negatively regulated?
Through post-translational modifications such as SUMOylation and O-GlcNAcylation, competitive displacement, and targeted degradation of chromatin-bound factors.
Why is negative regulation of chromatin binding important in cancer?
It controls androgen receptor chromatin interactions and nuclear hormone receptor stability, which are critical in prostate cancer and other hormone-driven cancers.
What methods study negative regulation of chromatin binding?
ChIP-seq, proteomics, Hi-C, CRISPR screens, and live-cell imaging are commonly used to measure chromatin occupancy and its regulation.
Does negative regulation of chromatin binding affect senescence?
Yes, mitochondria-to-nucleus retrograde signaling drives cytoplasmic chromatin formation and inflammation in senescence, linking this process to aging.
What is the role of CTCF in chromatin binding regulation?
CTCF is a chromatin architectural protein whose O-GlcNAcylation regulates 3D chromatin structure and its own chromatin interactions.
How does SUMOylation regulate chromatin binding?
SUMOylation modifies proteins such as the androgen receptor, altering their chromatin interactions and transcriptional outputs in prostate cancer cells.
Can CRISPR screens identify regulators of chromatin binding?
Yes, CRISPR knockout and activation screens can discover genes that negatively regulate chromatin binding in a genome-wide manner.
What cell models are used to study GO:0035562?
Knockout, point-mutation, knock-in, and overexpression cell models are used to test causality of candidate regulators.
Conclusion
GO:0035562, negative regulation of chromatin binding, is a fundamental biological process that controls which proteins occupy the genome and for how long. Through post-translational modifications, competitive interactions, and degradation, cells tightly regulate chromatin binding to shape transcription, genome architecture, and disease outcomes. Dysregulation of this process is implicated in cancer, senescence, meiotic defects, and circadian disorders. CRISPR-based models and functional genomics screens are essential tools to dissect these mechanisms and identify therapeutic targets. EDITGENE offers comprehensive services to accelerate research on negative regulation of chromatin binding.
References
- 1. Vizioli MG et al.. 2020. Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence.. Genes Dev 34(5-6):428-445 PMID: 32001510
- 2. Tang X et al.. 2024. The PTM profiling of CTCF reveals the regulation of 3D chromatin structure by O-GlcNAcylation.. Nat Commun 15(1):2813 PMID: 38561336
- 3. Tsai JM et al.. 2023. UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.. Mol Cell 83(15):2753-2767.e10 PMID: 37478846
- 4. Launonen KM et al.. 2024. Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells.. Nucleic Acids Res 52(16):9519-9535 PMID: 39106160
- 5. Zainu A et al.. 2024. FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading.. Nat Commun 15(1):7015 PMID: 39147779
- 6. Letkova D et al.. 2025. PBAF/cBAF reorganization on H3.3 chromatin regulates BMAL1 activity in the absence of circadian negative feedback.. Nat Commun 16(1):9000 PMID: 41068120
- 7. Bash R et al.. 2001. Yeast chromatin structure and regulation of GAL gene expression.. Prog Nucleic Acid Res Mol Biol 65:197-259 PMID: 11008489
- 8. Manzo SG et al.. 2024. Chromatin protein complexes involved in gene repression in lamina-associated domains.. EMBO J 43(21):5260-5287 PMID: 39322756
